Public Assessment Report Decentralised Procedure …

1 Public Assessment Report Decentralised Procedure MOLITA 200MG/ 25mg MODIFIED-RELEASE CAPSULES, HARD DIPYRIDAMOLE/ACETYLSALICYLIC ACID 200MG/ 25mg MODIFIED-RELEASE CAPSULES, HARD Procedure No: UK/H/4642/001/DC UK/H/5032/001/DC UK Licence No: PL 08553/0466 PL 08553/0473 Dr. Reddy s Laboratories (UK) Limited PAR Dipyridamole/Acetylsalicylic Acid 200mg/ 25mg modified-release caps UK/H/4642&5032/001/DC 2 LAY SUMMARY On 16 August 2012, Germany and the UK agreed to grant Marketing Authorisations to Dr Reddy s Laboratories (UK) Limited for the medicinal products Molita 200mg/ 25mg modified-release capsules, hard and Dipyridamole/Acetylsalicylic Acid 200mg/ 25mg modified-release capsules, hard (PL 08553/0466 UK/H/4642 & 5032/001/DC).

2 The licences were granted via the Decentralised Procedure (DCP), with the UK as Reference Member State (RMS). After the national phase, Marketing Authorisations were granted in the UK on 9 October 2012. These products contain two different medicines, dipyridamole and aspirin (acetylsalicylic acid). Both belong to a group of medicines called anti-thrombotic medicines . Aspirin also belongs to a group of medicines called non-steroidal anti-inflammatory drugs (NSAIDs) . They are used to stop blood clots forming. This medicine is used in people who have had a stroke or transient ischaemic attack (TIA) which are caused by a clot on the brain.

3 This medicine reduces the risk of this happening again. No new or unexpected safety concerns arose from this application and it was therefore judged that the benefits of taking these products outweigh the risks; hence, Marketing Authorisations were granted. PAR Dipyridamole/Acetylsalicylic Acid 200mg/ 25mg modified-release caps UK/H/4642&5032/001/DC 3 TABLE OF CONTENTS Module 1: Information about initial Procedure Page 4 Module 2: Summary of Product Characteristics Page 5 Module 3: Patient Information Leaflets Page 6 Module 4: Labelling Page 7 Module 5.

4 Scientific Discussion Page 10 I Introduction II About the Product III Scientific Overview and Discussion Quality aspects Non-clinical aspects Clinical aspects IV Overall conclusions Module 6 Steps taken after initial Procedure PAR Dipyridamole/Acetylsalicylic Acid 200mg/ 25mg modified-release caps UK/H/4642&5032/001/DC 4 Module 1 Product Name Molita 200mg/ 25mg modified-release capsules, hard Dipyridamole/Acetylsalicylic Acid 200mg/ 25mg modified-release capsules, hard Type of Application Generic, Article 10(1) Active Substances Acetylsalicylic acid and dipyridamole Form Modified-release capsule, hard Strength 200mg dipyridamole and 25mg acetylsalicylic acid MA Holder Dr.

5 Reddy s Laboratories (UK) Ltd, 6 Riverview Road, Beverley, East Yorkshire, HU17 0LD, United Kingdom Reference Member State (RMS) UK Concerned Member States (CMS) Germany Procedure Number UK/H/4642 & 5032/001/DC Timetable Day 210 16 August 2012 PAR Dipyridamole/Acetylsalicylic Acid 200mg/ 25mg modified-release caps UK/H/4642&5032/001/DC 5 Module 2 Summary of Product Characteristics The current approved UK version of the Summary of Product Characteristics (SmPC) for this product is available on the MHRA website. PAR Dipyridamole/Acetylsalicylic Acid 200mg/ 25mg modified-release caps UK/H/4642&5032/001/DC 6 Module 3 Patient Information Leaflet The current approved UK version of the Patient Information Leaflet (PIL) for this product is available on the MHRA website.

6 PAR Dipyridamole/Acetylsalicylic Acid 200mg/ 25mg modified-release caps UK/H/4642&5032/001/DC 7 Module 4 Labelling PAR Dipyridamole/Acetylsalicylic Acid 200mg/ 25mg modified-release caps UK/H/4642&5032/001/DC 8 PAR Dipyridamole/Acetylsalicylic Acid 200mg/ 25mg modified-release caps UK/H/4642&5032/001/DC 9 PAR Dipyridamole/Acetylsalicylic Acid 200mg/ 25mg modified-release caps UK/H/4642&5032/001/DC 10 Module 5 Scientific discussion during initial Procedure I INTRODUCTION Based on the review of the data on quality, safety and efficacy, the member states considered that the applications for Molita 200mg/ 25mg modified-release capsules, hard and Dipyridamole/Acetylsalicylic Acid 200mg/ 25mg modified-release capsules, hard (PL 08553/0466 UK/H/4642 & 5032/001/DC) could be approved.

7 These applications were submitted via the Decentralised Procedure , with the UK as Reference Member State (RMS) and Germany as Concerned Member State (CMS). These are prescription-only medicines indicated for the secondary prevention of ischaemic stroke and transient ischaemic attacks. These were applications made under the Decentralised Procedure (DCP), according to Article 10(1) of Directive 2001/83/EC, as amended, claiming to be a generic medicinal products of the originator product Asasantin Retard 200mg/ 25mg modified-release capsules, hard (Boehringer Ingelheim Limited), which was initially granted in the UK in May 1998.

8 Dipyridamole and acetylsalicylic acid (aspirin) are antiplatelet agents. It has been suggested that dipyridamole acts by increasing platelet cyclic 3 ,5 -adenosine monophosphate (cAMP) concentrations through the inhibition of adenosine uptake into platelets, affecting platelet aggregation caused by collagen, platelet-activating factor and ADP. Dipyridamole also inhibits platelet cyclic-3 ,5 - guanosine monophosphate (cGMP) phosphodiesterase, which in turn inhibits platelet activation and aggregation. Additionally, dipyridamole stimulates prostacyclin synthesis and potentiates the antiplatelet effects of prostacyclin.

9 These actions are generally reversible. Acetylsalicylic acid inactivates irreversibly the enzyme cyclo-oxygenase in platelets thus preventing the production of thromboxane A2, a powerful inducer of platelet aggregation and vasoconstriction. Whereas aspirin inhibits only platelet aggregation, dipyridamole in addition inhibits platelet activation and adhesion. Therefore, an additional benefit from combining both drugs can be expected. The combination of extended-release dipyridamole 200mg with immediate-release acetylsalicylic acid 25mg was studied in a large randomized trial in patients with recent history of ischaemic stroke or transient ischemic attack (TIA).

10 The combination showed significantly greater efficacy at reducing the risk of stroke compared to placebo but also compared to aspirin or dipyridamole monotherapies. Based on those findings, among others, extended-release dipyridamole with acetylsalicylic acid is currently licensed for the secondary prevention of ischaemic stroke and transient ischaemic attacks. No new non-clinical studies were conducted, which is acceptable given that the applications were based on being a generic medicinal product of an originator product that has been licensed for over 10 years. With the exception of the bioequivalence studies, no new clinical studies were conducted, which is acceptable given that the applications were based on being a generic medicinal products of an originator product that has been licensed for over 10 years.